Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Small molecules with antitubercular activity containing the pyrimidine motif in their structure
have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 …

New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread
of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease …

With the aim of fuelling open‐source, translational, early‐stage drug discovery activities, the
results of the recently completed antimycobacterial phenotypic screening campaign against …

Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are
urgently needed. Despite extensive drug discovery efforts, only a few promising candidates …

There is an urgent need to develop new and safer antitubercular agents that possess a
novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4 …

Over the past 2000 years, tuberculosis (TB) has killed more people than any other infectious
disease. In 2021, TB claimed 1.6 million lives worldwide, making it the second leading …

Mycobacterium tuberculosis is a major human pathogen and the causative agent for the
pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under …

The recent development and spread of extensively drug-resistant and totally drug-resistant
resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new …

Antibacterial drug development suffers from a paucity of targets whose inhibition kills
replicating and nonreplicating bacteria. The latter include phenotypically dormant cells …